Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2018-10-15 Capital/Financing Update
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the company, the securities being offered, the terms of the offering, risk factors, and other disclosures required for an initial or secondary public offering. This is not an annual report, earnings release, or any other type of financial or management report. It is a capital markets filing related to fundraising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement of a filing, supporting a high confidence level.
2018-10-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 4, 2018, by Moleculin Biotech, Inc. The content describes the entry into a material definitive agreement with Lincoln Park Capital Fund, LLC, specifically a purchase agreement and a registration rights agreement related to the sale of common stock. The document details the terms of the financing arrangement, including the commitment to purchase up to $20 million of common stock, conditions for sales, and limitations under NASDAQ rules. There are no financial statements or quarterly/yearly financial results presented. The document is an announcement of a capital raising agreement and financing activity, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing agreement, supporting a high confidence level.
2018-10-05 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 18, 2018. It specifically mentions that the company presented updated data slides at an investor presentation, and that the presentation is filed as Exhibit 99.1. The text does not contain detailed financial statements or analysis but refers to an investor presentation. The document length is 2985 characters, which is relatively short and mainly serves as a notice of the investor presentation event and filing. According to the classification rules, this type of document is best classified as an Investor Presentation (IP) since it focuses on presenting updated data slides to investors and is filed as an exhibit to the 8-K. It is not an Annual Report, Earnings Release, or other financial report, nor is it merely an announcement of a report publication. Therefore, the appropriate classification is IP with high confidence.
2018-09-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 13, 2018, for Moleculin Biotech, Inc. It specifically states in Item 2.02 that the company issued a press release announcing its financial results for the quarter ended June 30, 2018. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length of the document is 3057 characters, which is relatively short and consistent with a brief announcement rather than a full report. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). This document fits the description of an Earnings Release as it announces quarterly financial results and operational highlights without the full detailed report. Therefore, the appropriate classification is ER with high confidence.
2018-08-13 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-10 English
Regulatory Filings 2018
Regulatory Filings
2018-07-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.